References:
1. Luznik L, O’Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M, et
al. HLA-haploidentical bone marrow transplantation for hematologic
malignancies using nonmyeloablative conditioning and high-dose,
posttransplantation cyclophosphamide. Biology of Blood and Marrow
Transplantation. 2008;14(6):641-50.
2. Al Malki MM, Yang D, Labopin M, Afanasyev B, Angelucci E, Bashey A,
et al. Comparing transplant outcomes in ALL patients after
haploidentical with PTCy or matched unrelated donor transplantation.
Blood advances. 2020;4(9):2073-83.
3. Law AD, Salas MQ, Lam W, Michelis FV, Thyagu S, Lipton JH, et al.
Reduced-intensity conditioning and dual T lymphocyte suppression with
antithymocyte globulin and post-transplant cyclophosphamide as
graft-versus-host disease prophylaxis in haploidentical hematopoietic
stem cell transplants for hematological malignancies. Biology of Blood
and Marrow Transplantation. 2018;24(11):2259-64.
4. Wang Y, Wu D-P, Liu Q-F, Xu L-P, Liu K-Y, Zhang X-H, et al. Low-dose
post-transplant cyclophosphamide and anti-thymocyte globulin as an
effective strategy for GVHD prevention in haploidentical patients.
Journal of hematology & oncology. 2019;12(1):1-9.
5. Xu X, Yang J, Cai Y, Li S, Niu J, Zhou K, et al. Low dose
anti-thymocyte globulin with low dose posttransplant cyclophosphamide
(low dose ATG/PTCy) can reduce the risk of graft-versus-host disease as
compared with standard-dose anti-thymocyte globulin in haploidentical
peripheral hematopoietic stem cell transplantation combined with
unrelated cord blood. Bone marrow transplantation. 2021;56(3):705-8.
6. Makanga DR, Guillaume T, Willem C, Legrand N, Gagne K, Cesbron A, et
al. Posttransplant Cyclophosphamide and Antithymocyte Globulin versus
Posttransplant Cyclophosphamide as Graft-versus-Host Disease Prophylaxis
for Peripheral Blood Stem Cell Haploidentical Transplants: Comparison of
T Cell and NK Effector Reconstitution. The Journal of Immunology.
2020;205(5):1441-8.
7. Passweg J, Baldomero H, Bader P, Bonini C, Duarte R, Dufour C, et al.
Use of haploidentical stem cell transplantation continues to increase:
the 2015 European Society for Blood and Marrow Transplant activity
survey report. Bone marrow transplantation. 2017;52(6):811-7.
8. Phelan R, Arora, M., Chen, M. . Current use and outcome of
hematopoietic stem cell transplantation: CIBMTR US summary slides. 2020.
9. Bhushan V, Mathews J, Vance E, Escobar C, Kurre J, Potter J, et al.
Salvage Therapy for Graft Rejection with Second Haploidentical
Allogeneic Stem Cell Transplantation (Haplo-HCT) from a Second Related
Donor. Biology of Blood and Marrow Transplantation. 2015;21(2):S297.
10. Prata PH, Resche-Rigon M, Blaise D, Socié G, Rohrlich P-S, Milpied
N, et al. Outcomes of salvage haploidentical transplant with
post-transplant cyclophosphamide for rescuing graft failure patients: a
report on behalf of the francophone society of bone marrow
transplantation and cellular therapy. Biology of Blood and Marrow
Transplantation. 2019;25(9):1798-802.
11. Yoshihara S, Ikegame K, Taniguchi K, Kaida K, Kim E, Nakata J, et
al. Salvage haploidentical transplantation for graft failure using
reduced-intensity conditioning. Bone marrow transplantation.
2012;47(3):369-73.
12. Epperla N, Pasquini M, Pierce K, Drobyski W, Rizzo J, Horowitz M, et
al. Salvage haploidentical hematopoietic cell transplantation for graft
rejection following a prior haploidentical allograft. Bone marrow
transplantation. 2017;52(1):147-50.
13. Giammarco S, Raiola AM, Di Grazia C, Bregante S, Gualandi F, Varaldo
R, Chiusolo P, Sora F, Sica S, Laurenti L, Metafuni E. Second
haploidentical stem cell transplantation for primary graft failure. Bone
Marrow Transplantation. 2020 Dec 16:1-6.
14. Moreland L, Bate G, Kirkpatrick P. Abatacept. Nature Reviews Drug
Discovery. 2006;5(3):185-6.
15. Zhu Z, Fan L, Wang Q. Simultaneous blockade of costimulatory signals
CD28-CD80 and CD40-CD154 combined with monoclonal antibody against CD25
induced a stable chimerism and tolerance without graft-versus-host
disease in rat. European Surgical Research. 2011;46(3):109-17.
16. Tiwari D, Horan J, Langston A, Qayed M, Carr J, Renfroe H, et al. A
first-in-disease trial of in vivo costimulation blockade for acute GvHD
prevention: the addition of abatacept to standard GvHD prophylaxis
controls early CD4+ T cell proliferation and is associated with low
rates of severe acute GvHD. American Society of Hematology; 2012.
17. Koura DT, Horan JT, Langston AA, Qayed M, Mehta A, Khoury HJ, et al.
In vivo T cell costimulation blockade with abatacept for acute
graft-versus-host disease prevention: a first-in-disease trial. Biology
of Blood and Marrow Transplantation. 2013;19(11):1638-49.
18. Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, et
al. National Institutes of Health consensus development project on
criteria for clinical trials in chronic graft-versus-host disease: I.
The 2014 diagnosis and staging working group report. Biology of Blood
and Marrow Transplantation. 2015;21(3):389-401. e1.
19. Przepiorka D, Weisdorf D, Martin P, Klingemann H, Beatty P, Hows J,
et al. 1994 Consensus conference on acute GVHD grading. Bone marrow
transplantation. 1995;15(6):825-8.
20. Raiola AM, Dominietto A, di Grazia C, Lamparelli T, Gualandi F,
Ibatici A, et al. Unmanipulated haploidentical transplants compared with
other alternative donors and matched sibling grafts. Biology of Blood
and Marrow Transplantation. 2014;20(10):1573-9.
21. Raj K, Pagliuca A, Bradstock K, Noriega V, Potter V, Streetly M, et
al. Peripheral blood hematopoietic stem cells for transplantation of
hematological diseases from related, haploidentical donors after
reduced-intensity conditioning. Biology of Blood and Marrow
Transplantation. 2014;20(6):890-5.
22. Solomon SR, Solh M, Morris LE, Holland HK, Bashey A. Myeloablative
conditioning with PBSC grafts for T cell-replete haploidentical donor
transplantation using posttransplant cyclophosphamide. Advances in
hematology. 2016;2016.
23. Sharma A, Rastogi N, Chatterjee G, Kapoor R, Nivargi S, Yadav SP.
Haploidentical Stem Cell Transplantation With Posttransplant
Cyclophosphamide for Pediatric Acute Leukemia is Safe and Effective.
Journal of pediatric hematology/oncology. 2020.
24. Pérez‐Martínez A, Ferreras C, Pascual A, Gonzalez‐Vicent M, Alonso
L, Badell I, et al. Haploidentical transplantation in high‐risk
pediatric leukemia: A retrospective comparative analysis on behalf of
the Spanish working Group for bone marrow transplantation in children
(GETMON) and the Spanish Grupo for hematopoietic transplantation (GETH).
American journal of hematology. 2020;95(1):28-37.
25. Katsanis E, Sapp LN, Reid SC, Reddivalla N, Stea B. T-Cell replete
myeloablative haploidentical bone marrow transplantation is an effective
option for pediatric and young adult patients with high-risk hematologic
malignancies. Frontiers in Pediatrics. 2020;8.
26. Jaiswal SR, Chakrabarti A, Chatterjee S, Ray K, Chakrabarti S.
Haploidentical transplantation in children with unmanipulated peripheral
blood stem cell graft: The need to look beyond post‐transplantation
cyclophosphamide in younger children. Pediatric transplantation.
2016;20(5):675-82.
27. Watkins B, Qayed M, McCracken C, Bratrude B, Betz K, Suessmuth Y, et
al. Phase II Trial of Costimulation Blockade With Abatacept for
Prevention of Acute GVHD. Journal of Clinical Oncology. 2021:JCO.
20.01086.
28. Ngwube A, Shah N, Godder K, Jacobsohn D, Hulbert ML, Shenoy S.
Abatacept is effective as GVHD prophylaxis in unrelated donor stem cell
transplantation for children with severe sickle cell disease. Blood
Advances. 2020;4(16):3894-9.
29. Khandelwal P, Yeh RF, Yu L, Lane A, Dandoy CE, El-Bietar J, et al.
Graft Versus Host Disease Prophylaxis With Abatacept Reduces Severe
Acute Graft Versus Host Disease in Allogeneic Hematopoietic Stem Cell
Transplant for Beta Thalassemia Major with Busulfan, Fludarabine, and
Thiotepa. Transplantation. 2020.
30. Jaiswal SR, Bhakuni P, Zaman S, Bansal S, Bharadwaj P, Bhargava S,
et al. T cell costimulation blockade promotes transplantation tolerance
in combination with sirolimus and post-transplantation cyclophosphamide
for haploidentical transplantation in children with severe aplastic
anemia. Transplant immunology. 2017;43:54-9.
31. Chaudhury S, Laskowski J, Rangarajan HG, Abraham A, Haight AE,
Guilcher GM, et al. Abatacept for GVHD prophylaxis after hematopoietic
stem cell transplantation (HCT) for pediatric sickle cell disease (SCD):
a sickle transplant alliance for research (STAR) trial. Biology of Blood
and Marrow Transplantation. 2018;24(3):S91.
32. Chen Y, Fukuda T, Thakar MS, Kornblit BT, Storer BE, Santos EB, et
al. Immunomodulatory effects induced by cytotoxic T lymphocyte antigen 4
immunoglobulin with donor peripheral blood mononuclear cell infusion in
canine major histocompatibility complex–haplo-identical
non-myeloablative hematopoietic cell transplantation. Cytotherapy.
2011;13(10):1269-80.
33. Kean L, Hamby K, Koehn B, Lee E, Coley S, Stempora L, et al. NK
cells mediate costimulation blockade‐resistant rejection of allogeneic
stem cells during nonmyeloablative transplantation. American journal of
transplantation. 2006;6(2):292-304.
34. Peng Y, Luo G, Zhou J, Wang X, Hu J, Cui Y, et al. CD86 is an
activation receptor for NK cell cytotoxicity against tumor cells. PLoS
One. 2013;8(12):e83913.
35. Jaiswal SR, Bhakuni P, Joy A, Kaushal S, Chakrabarti A, Chakrabarti
S. CTLA4Ig primed donor lymphocyte infusion: a novel approach to
immunotherapy after haploidentical transplantation for advanced
leukemia. Biology of Blood and Marrow Transplantation.
2019;25(4):673-82.
36. McCurdy SR, Kanakry JA, Showel MM, Tsai HL, Bolaños-Meade J, Rosner
GL, et al. Risk-stratified outcomes of nonmyeloablative
HLA-haploidentical BMT with high-dose posttransplantation
cyclophosphamide. Blood. 2015;125(19):3024-31.
37. Khandelwal P, Chaturvedi V, Owsley E, Lane A, Heyenbruch D, Lutzko
CM, et al. CD38(bright)CD8(+) T Cells Associated with the Development of
Acute GVHD Are Activated, Proliferating, and Cytotoxic Trafficking
Cells. Biology of blood and marrow transplantation : journal of the
American Society for Blood and Marrow Transplantation. 2020;26(1):1-6.
38. Grogan BM, Tabellini L, Storer B, Bumgarner TE, Astigarraga CC,
Flowers ME, et al. Activation and expansion of CD8+ T effector cells in
patients with chronic graft-versus-host disease. Biology of Blood and
Marrow Transplantation. 2011;17(8):1121-32.
39. Comoli P, Locatelli F, Moretta A, Montagna D, Calcaterra V, Cometa
A, et al. Human alloantigen-specific anergic cells induced by a
combination of CTLA4-Ig and CsA maintain anti-leukemia and anti-viral
cytotoxic responses. Bone marrow transplantation. 2001;27(12):1263-73.